{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-22-000195","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.296111+00:00","generated_at":"2026-06-21T06:17:48.383285+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Humacyte amends bylaws to strengthen director nomination rules and align with Delaware law","bullets":["Board approved amended bylaws effective Dec 8, 2022, adding universal proxy rule compliance requirements (Rule 14a-19).","Stockholders nominating directors must state intent to solicit proxies and provide evidence of compliance upon request.","Company may disregard proxies/votes if nominating stockholder fails to meet Rule 14a-19 requirements.","Bylaws updated for Delaware law: clarify virtual meeting adjournment procedures, eliminate stockholder list inspection requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-22-000195","json":"https://secwatch.observer/filing/0001818382-22-000195.json","markdown":"https://secwatch.observer/filing/0001818382-22-000195.md","text":"https://secwatch.observer/filing/0001818382-22-000195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/0001818382-22-000195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/huma-20221208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:17:48.383285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0306ee034680c9be3b1d236774877ce3c92f4e5c","claim":"Humacyte, Inc.: The board of directors approved amended and restated bylaws, effective immediately (effective 2022-12-08).","evidence_excerpt":"On December 8, 2022, the board of directors of Humacyte, Inc. (the “Company”) approved amended and restated by laws, which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000195/0001818382-22-000195-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}